Department of Cardiology, Rigshospitalet University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Europace. 2023 Mar 30;25(3):978-988. doi: 10.1093/europace/euac256.
Late gadolinium enhancement cardiac magnetic resonance (CMR) permits characterization of left ventricular ischaemic scars. We aimed to evaluate if scar core mass, border zone (BZ) mass, and BZ channels are risk markers for subsequent ventricular arrhythmia (VA) in ST-segment elevation myocardial infarction (STEMI).
A sub-study of the DANish Acute Myocardial Infarction-3 multi-centre trial and Danegaptide phase II proof-of-concept clinical trial in which a total of 843 STEMI patients had a 3-month follow-up CMR. Of these, 21 patients subsequently experienced VA during 100 months of follow-up and were randomly matched 1:5 with 105 controls. A VA event was defined as: ventricular tachycardia, ventricular fibrillation, or sudden cardiac death. Ischaemic scar characteristics were automatically detected by specialized software. We included 126 patients with a median left ventricular ejection fraction of 51.0 ± 11.6% in cases with VA vs. 55.5 ± 8.5% in controls (P = 0.10). Cases had a larger mean BZ mass and more often BZ channels compared to controls [BZ mass: 17.2 ± 10.3 g vs. 10.3 ± 6.0 g; P = 0.0002; BZ channels: 17 (80%) vs. 44 (42%); P = 0.001]. A combination of ≥17.2 g BZ mass and the presence of BZ channels was five times more prevalent in cases vs. controls (P ≤ 0.00001) with an odds ratio of 9.40 (95% confidence interval 3.26-27.13; P ≤ 0.0001) for VA. This identified cases with 52% sensitivity and 90% specificity.
CONCLUSION(S): Scar characterization with CMR indicates that a combination of ≥17.2 g BZ mass and the presence of BZ channels had the strongest association with subsequent VA in STEMI patients.
CLINICALTRIALS.GOV: Unique identifier: NCT01435408 (DANAMI 3-iPOST and DANAMI 3-DEFER), NCT01960933 (DANAMI 3-PRIMULTI), and NCT01977755 (Danegaptide).
钆延迟增强心脏磁共振(CMR)可用于左心室缺血性瘢痕的特征描述。本研究旨在评估在 ST 段抬高型心肌梗死(STEMI)患者中,瘢痕核心质量、边界区(BZ)质量和 BZ 通道是否为随后发生室性心律失常(VA)的风险标志物。
该研究是 DANish Acute Myocardial Infarction-3 多中心试验和 Danegaptide 二期概念验证临床试验的子研究,共有 843 例 STEMI 患者在 3 个月时进行了 CMR 随访。其中,21 例患者在 100 个月的随访期间发生了 VA,并随机与 105 例对照组进行了 1:5 的匹配。VA 事件定义为:室性心动过速、心室颤动或心脏性猝死。缺血性瘢痕特征通过专门的软件自动检测。我们纳入了 126 例左心室射血分数中位数为 51.0±11.6%的患者,其中 VA 组为 21 例,对照组为 105 例,对照组为 55.5±8.5%(P=0.10)。与对照组相比,VA 组的平均 BZ 质量更大,BZ 通道更常见[BZ 质量:17.2±10.3g 比 10.3±6.0g;P=0.0002;BZ 通道:17(80%)比 44(42%);P=0.001]。在 VA 组中,BZ 质量≥17.2g 和存在 BZ 通道的组合更为常见,其比值比为 9.40(95%置信区间 3.26-27.13;P≤0.0001),VA 的敏感性为 52%,特异性为 90%。
CMR 瘢痕特征表明,BZ 质量≥17.2g 和存在 BZ 通道的组合与 STEMI 患者随后发生 VA 的相关性最强。
唯一标识符:NCT01435408(DANAMI 3-iPOST 和 DANAMI 3-DEFER)、NCT01960933(DANAMI 3-PRIMULTI)和 NCT01977755(Danegaptide)。